CASI Pharmaceuticals Gets FDA Approval For Investigational New Drug CID-103 In Treating Immune Thrombocytopenia (ITP).

Ractigen Therapeutics Gains NMPA Clearance to Begin Phase 1 Trials of RAG-17 in Chinese SOD1-ALS Patients.

With Weekly Dosing, Insulin Efsitora Alfa Achieves A1C Reduction and Matches Safety of Daily Insulin.

Biopharmaceutical firm Iterion Therapeutics has initiated a Phase 1b/2a clinical trial for its lead drug candidate, tegavivint, which is designed to inhibit Transducin beta-like protein 1 (TBL1).

Immune-Onc Therapeutics has entered into a clinical trial collaboration with Roche to assess the potential of IO-108 as a first-line treatment for hepatocellular carcinoma (HCC).

NextPoint Therapeutics has initiated a Phase 1 clinical trial for NPX887, a drug designed to target solid tumors with high expression of the HHLA2/B7-H7 antigen.

Monopar Therapeutics Inc. has been given the green light by the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 dosimetry study for its innovative radiopharmaceutical, MNPR-101-Zr.

Arvinas Inc. has initiated its Phase 1 clinical trial of ARV-102, a novel oral PROTAC® protein degrader aimed at treating neurodegenerative diseases.

Aleta Biotherapeutics, a company specializing in immuno-oncology, has initiated a Phase 1/2 clinical trial for its innovative biologic, ALETA-001.

ReCode Therapeutics, a company specializing in genetic medicine, has initiated a Phase 1 clinical trial for RCT2100, an innovative inhaled treatment for cystic fibrosis (CF).

The study focused on the use of paxalisib, an oral medication that inhibits both PI3K and mTOR, alongside radiation therapy for patients with brain metastases from solid tumors that have a PI3K pathway mutation.

Lutris Pharma has published positive results from a phase 1/2 clinical trial of their lead compound, LUT014.